JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...
JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers ...
Shares of Promis Neurosciences (PMN) have gained 3.3% over the past four weeks to close the last trading session at $10.75, but there could still be a solid upside left in the stock if short-term ...
The event will feature leading companies and key opinion leaders in Alzheimer’s disease research, discussing the current treatment landscape, development of disease modifying therapies and symptom ...
During these conferences, Neil Warma, CEO of ProMIS Neurosciences, will discuss the Company's EpiSelect™ platform and differentiated approach to developing therapeutics for neurodegenerative diseases ...
"You’ll get the inside scoop DIRECT from me, President Trump," the email promised to supporters who quickly paid to become a "National Security Briefing Member" The White House via X Account/Anadolu ...
Leaked API keys are nothing new, but the scale of the problem in front-end code has been largely a mystery - until now. Intruder’s research team built a new secrets detection method and scanned 5 ...
(RTTNews) - ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, has announced on Friday a private investment in public equity financing of up to approximately $175 million. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results